The Benevolent Platform™ drives our three revenue streams. Our business model offers multiple routes for revenue generation and value creation.

Established business

End-to-end drug discovery

Drug discovery offerings

  • Platform enables novel discoveries throughout the drug discovery process
  • Continuing to expand on our industry-leading collaborations
  • Validated by collaborations with AstraZeneca and Merck

High value collaborations

Upfront payments + milestones + royalties

Preclinical and clinical development pipeline

Platform generated assets

  • Five high potential assets
  • Potentially first-in-class or best-in-class assets providing novel therapeutic opportunities
  • Progressing assets to significant inflection points

Mid to long-term value creation

Upfront fees + milestones + royalties

New expansion opportunities

Knowledge Exploration Tools

New customisable SaaS products

  • Suite of AI products that surface data, perform analysis, and give scientific recommendations
  • BenAI-Q and BenAI Research Assistant products enabling enhanced decision making
  • Building from our core technologies to develop innovative ways to serve customers and their scientists

Highly scalable, recurring revenue

Fees for setup, platform licences and seats + ongoing support services


Reach your full research and development potential.

Speak to our business development team.

Contact us

Hear more about investment opportunities.

Speak to our investor relations team

Contact us